prostate-report.org

PSA kinetics do not predict pathology in men on active surveillance

A new study at Johns Hopkins University School of Medicine aimed to assess the predictive ability of prostate-specific antigen (PSA) velocity (PSAV) and doubling time (PSADT) for biopsy progression and adverse pathology at prostatectomy among men with low-risk prostate cancer enrolled on an active-surveillance program.

Study concluded that postdiagnostic PSA kinetics (i.e., PSA doubling time and PSA velocity) do not reliably predict adverse pathology and should not be used to replace annual surveillance biopsy for monitoring men on active surveillance.